The Cleveland Clinic Foundation

Other

Jonathan D Smith

Stanley Leon Hazen

Marc S Penn

Renliang Zhang

Lemin Zheng

Michael Kinter

Shuhui Wang Lorkowski

L Hazen Stanley

Provided herein are compositions, systems, kits, and methods for performing an apoA1 exchange assay to determine the risk of MACE and/or for conducting an action based on the assay results. In some embodiments, methods are provided for generating, or receiving, a report that graphically displays: i) the subjects ApoA1 exchange rate in a sample as lower than a control or threshold value, and ii) the subjects risk of a major adverse cardiac event (MACE) and/or cardiovascular disease as being higher than normal.

ApoA1 exchange rate assays in serum

A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.

Oxidant resistant apolipoprotein A-1 and mimetic peptides

A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprises the step of administering to the subject a therapeutically effective amount of a polypeptide that is capable promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino acid sequence of SEQ ID NO:1, in which each X in SEQ ID NO:1 is a phenylalanine amino acid.

Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

Risk markers for cardiovascular disease

Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

A method for the treatment of cardiovascular disease or disorder in a subject in need thereof, the method comprising the steps of administering an ApoA1 mimetic that is capable of promoting cholesterol efflux from lipid loaded cells in the subject, wherein the ApoA1 mimetic has an amino acid sequence that includes at least a portion of the amino acid sequence of ApoA1 or a mimetic of ApoA1 that contains at least one tryptophan, at least one tryptophan from the ApoA1 or mimetic of the ApoA1 being substituted with an oxidant resistant amino acid in the amino acid sequence of the ApoA1 mimetic.

A method for processing a fruit, such as a cranberry, includes cutting open a fruit and partially removing a highly concentrated juice fraction from the fruit when pressed while maintained within a sub-freezing temperature range. The skin of the frozen fruit is penetrated by being sliced or punctured facilitating juice extraction and subsequently infusion, such as by vacuum. Before extraction, the sliced fruit is uniformly tempered to a temperature below 32&#xb0; F., more specifically to between 26&#xb0; F. and 32&#xb0; F. To extract juice, the fruit is pressed, removing from about 40% to 65% by weight of the liquid, yielding a concentrated fruit juice, with significantly enhanced brix, acid, and color, and a partially dehydrated fruit piece, with significantly reduced brix, acid, and color, and still within the given sub-freezing temperature range. The fruit piece may then be infused, such as under vacuum while being rotated, with a variety of ingredients.

Growing community of inventors

Shaker Heights, OH, United States of America

Jonathan D Smith